ライフサイエンスコーパス: monocyte chemotactic protein-1

1 oteins (interferon gamma-induced protein-10, monocyte chemotactic protein-1).

2 NTES, and -24.9% (2, -44.8 [P = 0.0656]) for monocyte chemotactic protein 1.

3 lls, possibly via release of IL-6, IL-8, and monocyte chemotactic protein 1.

4 els of the potent macrophage chemoattractant monocyte chemotactic protein-1.

5 nd MIP-1beta with donor-dependent changes in monocyte chemotactic protein-1.

6 m cytokines, including interleukin-1beta and monocyte chemotactic protein-1.

7 ges also migrated toward galectin-3, but not monocyte chemotactic protein-1.

8 y macrophage inflammatory protein 1-alpha or monocyte chemotactic protein-1.

9 NADPH oxidase (NOX) 2, NOX4, E-selectin, and monocyte chemotactic protein-1.

10 filtration into lesions, and lower levels of monocyte chemotactic protein-1.

11 7,macrophage inflammatory protein-1beta, and monocyte chemotactic protein-1.

12 flammatory protein 2 and KC, and higher lung monocyte chemotactic protein-1.

13 ted to play a direct role in angiogenesis is monocyte-chemotactic protein-1.

14 , but not in pre-bypass or perfusate plasma (monocyte chemotactic protein-1 = 29.5 +/- 2.1 pmoles/l v

15 rbitrary units [AU], P = 0.03) and increased monocyte chemotactic protein-1 (3.11 +/- 0.41 nonsmokers

16 7.5-folds), IL-12 (2.3-folds) and chemokines monocyte chemotactic protein 1 (4.5-folds), MIG (4.4-fol

17 +/- 535 vs. 463 +/- 236 pg/mL, p = .02), and monocyte chemotactic protein-1 (7517 +/- 1612 vs. 2983 +

18 pithelial damage was a localized increase in monocyte chemotactic protein 1, a chemokine known to be

19 In addition, monocyte chemotactic protein-1, a potent mononuclear cel

20 y, we hypothesized that the chemokine ligand monocyte chemotactic protein-1, also designated CC chemo

21 creased mRNA and secreted protein levels for monocyte chemotactic protein 1, an effect that could con

22 ensitive regional lymph node cultures, while monocyte-chemotactic protein-1, an important macrophage

23 e the most abundant, but CC chemokines (CCL2/monocyte chemotactic protein 1 and CCL3/macrophage infla

24 in the mRNA stability of the key chemokines monocyte chemotactic protein 1 and IL-8, an elevation of

25 There was also upregulation of monocyte chemotactic protein 1 and macrophage inflammato

26 to attract macrophages via the secretion of monocyte chemotactic protein 1 and promote endothelial c

27 uch as vascular cell adhesion molecule-1 and monocyte chemotactic protein-1 and -3, which function to

28 ncluding mRNA for TNF-alpha, IL-1beta, IL-6, monocyte chemotactic protein-1 and a variety of macropha

29 C expression of adhesion molecules including monocyte chemotactic protein-1 and complement and platel

30 A interference-mediated knockdown assays and monocyte chemotactic protein-1 and intercellular adhesio

31 and expression of the pro-inflammatory genes monocyte chemotactic protein-1 and interleukin-6.

32 r stress induced p38-dependent expression of monocyte chemotactic protein-1 and interleukin-8 in porc

33 ion in response to proatherogenic cytokines (monocyte chemotactic protein-1 and macrophage colony-sti

34 pancreatic induction of the chemoattractants monocyte chemotactic protein-1 and macrophage inflammato

35 influx was preceded by an acute elevation in monocyte chemotactic protein-1 and macrophage inflammato

36 imulated macrophages secreted the chemokines monocyte chemotactic protein-1 and MIP-1beta in a manner

37 motaxis, concurrently lowering the levels of monocyte chemotactic protein-1 and MIP-1beta.

38 With the exception of low levels of monocyte chemotactic protein-1 and RANTES, culture with

39 macrophages exhibited impaired chemotaxis to monocyte chemotactic protein-1 and showed reduced abilit

40 w and directly recruit MM cells through both monocyte chemotactic protein-1 and stromal cell-derived

41 ecules vascular cell adhesion molecule-1 and monocyte chemotactic protein-1 and the consequential adh

42 PAI-1, the secretion of TNFalpha, IL-8, and monocyte chemotactic protein-1 and the formation of PAI-

43 Monocyte chemotactic protein-1 and transforming growth f

44 the aortic arch, and more abundant mRNA for monocyte chemotactic protein-1 and tumor necrosis factor

45 o lymphocyte-attracting chemokines assessed, monocyte-chemotactic protein-1 and macrophage-inflammato

46 expression of chemokines (eg, interleukin-8, monocyte chemotactic protein-1) and other proinflammator

47 10 (IFNgamma-inducible 10-kd protein), CCL2 (monocyte chemotactic protein 1), and CCL19 (macrophage i

48 kines and chemokines (HMGB1, TNFalpha, IL-8, monocyte chemotactic protein-1), and formation of PAI-1/

49 oteins (interferon gamma-induced protein-10, monocyte chemotactic protein-1), and signal transducer a

50 crosis factor-alpha; MIP-1alpha/beta; MCP-1 (monocyte chemotactic protein-1); and RANTES.

51 tinocyte chemoattractant, interleukin 1beta, monocyte chemotactic protein 1, and granulocyte colony-s

52 NF-kappaB, monocyte chemotactic protein 1, and inducible nitric oxi

53 activity and the release of IL-1beta, IL-6, monocyte chemotactic protein 1, and macrophage inflammat

54 increases were observed for IL-1beta, IL-6, monocyte chemotactic protein 1, and MyD88 mRNA.

55 inhibitory protein (MIP)-1alpha, MIP-1beta, monocyte chemotactic protein 1, and RANTES (regulated up

56 , MIP-2, interferon gamma-inducible protein, monocyte chemotactic protein 1, and T-cell activation ge

57 locyte macrophage colony-stimulating factor, monocyte chemotactic protein-1, and beta2-microglobulin

58 peptide, vascular endothelial growth factor, monocyte chemotactic protein-1, and blood pressure.

59 ncentrations of IL-12p40, IL-18, RANTES, and monocyte chemotactic protein-1, and elevated production

60 ncluded secretion of interferon-gamma, IL-2, monocyte chemotactic protein-1, and IL-12/IL-23 and prol

61 les, such as platelet-derived growth factor, monocyte chemotactic protein-1, and IL-13, were also red

62 ction of inflammatory proteins (e.g., IL-17, monocyte chemotactic protein-1, and IL-22) in lymphocyte

63 normal t expressed and presumably secreted, monocyte chemotactic protein-1, and interferon-gamma ind

64 or necrosis factor-alpha, interleukin-1beta, monocyte chemotactic protein-1, and macrophage inflammat

65 its target genes such as interleukin-1beta, monocyte chemotactic protein-1, and macrophage inflammat

66 rosis factor-alpha, interferon-gamma, IL-10, monocyte chemotactic protein-1, and macrophage inflammat

67 erleukin-8, interferon-inducible protein-10, monocyte chemotactic protein-1, and macrophage inflammat

68 nduced inflammatory mediators, such as IL-6, monocyte chemotactic protein-1, and P-selectin, after re

69 tumor necrosis factor-alpha, interleukin-6, monocyte chemotactic protein-1, and PAE-specific immunog

70 ha, IL-1beta, and IL-6; the chemokines IL-8, monocyte chemotactic protein-1, and RANTES; and the adhe

71 , granulocyte colony-stimulating factor, and monocyte chemotactic protein-1, and reduced granulocyte-

72 , vascular endothelial growth factor, IL-12, monocyte chemotactic protein-1, and S100A8/A9, as well a

73 nnective tissue growth factor, endothelin-1, monocyte chemotactic protein-1, and spermidine/spermine

74 ression of the chemokines, interleukin-8 and monocyte chemotactic protein-1, and the antifibrinolytic

75 factor, interleukin-6, resistin, leptin, and monocyte chemotactic protein-1, and the upregulation of

76 2 (putative murine homologue of human IL-8), monocyte chemotactic protein-1, and TNF-alpha; and a red

77 ase in bronchoalveolar lavage interleukin-6, monocyte chemotactic protein-1, and tumor necrosis facto

78 rations of CD40 antigen, CD40 ligand, IL-16, monocyte chemotactic protein-1, and vascular cell adhesi

79 vation normal T cell expressed and secreted, monocyte chemotactic protein-1, and vascular endothelial

80 sally to naive mice induced eotaxin, RANTES, monocyte-chemotactic protein-1, and KC expression along

81 leukin-6; macrophage inflammatory protein-2; monocyte chemotactic protein-1; and regulated on activat

82 Of the mRNAs tested, only those encoding monocyte chemotactic protein-1 (approximately 2-fold ove

83 depended on Gr-1(+) cells, and we implicated monocyte chemotactic protein-1 as a potential mediator.

84 rkers: plasminogen activator inhibitor-1 and monocyte chemotactic protein-1 by 4.5- and 4.0-fold, res

85 increase in plasma markers of inflammation (monocyte chemotactic protein-1, C-reactive protein), the

86 increased circulating TGF-beta1, TGF-beta2, monocyte chemotactic protein-1, C-reactive protein, inte

87 /CXC chemokine ligand 10, interleukin 8, and monocyte chemotactic protein-1/CC chemokine ligand 2.

88 ny stimulating factor (GM-CSF), IL-8, IL-18, monocyte chemotactic protein-1 (CCL2) (MCP-1), tissue pl

89 ponses were comparable with those induced by monocyte-chemotactic protein-1 (CCL2), but lower than th

90 yD88 (MyD88(DN)) decreased the production of monocyte chemotactic protein-1/CCL2 (P=0.000), IL-8/CXCL

91 ctivation (P<0.05) and significantly reduced monocyte chemotactic protein-1/CCL2 (P=0.000), IL-8/CXCL

92 yesian Network suggested that the chemokines monocyte chemotactic protein-1/CCL2 and monokine induced

93 Plasma levels of chemokines (monocyte chemotactic protein-1/CCL2, inducible protein-1

94 ANTES, IFN-inducible protein 10 (IP-10), and monocyte chemotactic protein 1 chemokine mRNA were detec

95 tivity, resulting in decreased expression of monocyte chemotactic protein-1/chemokine (C-C motif) lig

96 ntly lower levels of the chemokines IL-8 and monocyte chemotactic protein-1 compared with mothers of

97 reduction in TNF-alpha, IL-1beta, IL-8, and monocyte chemotactic protein 1 concentrations (P < 0.05)

98 Monocyte chemotactic protein-1 concentrations were decre

99 antly lower plasma sRAGE, interleukin-6, and monocyte chemotactic protein-1 concentrations.

100 oduced by arterial occlusion in wild-type or monocyte chemotactic protein-1-deficient mice.

101 es macrophage-inflammatory protein-1alpha or monocyte chemotactic protein-1 did not inhibit Th1 selec

102 except that tumor necrosis factor alpha and monocyte chemotactic protein 1 expression was only eleva

103 macrophages, we showed that mCAT suppressed monocyte chemotactic protein-1 expression by decreasing

104 erleukin (IL)-6, inducible nitric oxide, and monocyte chemotactic protein-1 expression relative to st

105 In PARP-1(-/-) macrophages, monocyte chemotactic protein-1 expression was severely i

106 inflammatory gene (toll-like receptor 4 and monocyte chemotactic protein 1) expression, and ceramide

107 chemotactic and activating C-C chemokine JE/monocyte chemotactic protein-1 has been proposed.

108 its major ligand, chemokine ligand 2 (CCL2)/monocyte chemotactic protein-1, have been found to influ

109 terleukin-8, interleukin-10, interleukin-18, monocyte chemotactic protein-1, high-mobility group box-

110 primary response gene (88), TLR9, TNF-alpha, monocyte chemotactic protein-1, IFN-gamma inducible prot

111 isregulation of tumor necrosis factor alpha, monocyte chemotactic protein 1, IL-10, transforming grow

112 thelial cells results in increased levels of monocyte chemotactic protein 1, IL-8, and IL-6 cytokines

113 nd KC; IL-4 also increased the production of monocyte-chemotactic protein-1; IL-13 and IL-4 induced e

114 matrix metalloproteinase 3, IL-6, IL-8, and monocyte chemotactic protein 1 in RASFs.

115 glia cells expressed IL-6 and the chemokine monocyte chemotactic protein 1 in response to IL-1beta s

116 sion of growth differentiation factor-15 and monocyte chemotactic protein-1 in a murine macrophage ce

117 enge had no additional effect on circulating monocyte chemotactic protein-1 in either genotype.

118 macrophage inflammatory protein-1alpha, and monocyte chemotactic protein-1 in human peripheral blood

119 kin-1beta, tissue necrosis factor-alpha, and monocyte chemotactic protein-1 in the glycogen model and

120 tory function, and increased basal levels of monocyte chemotactic protein-1 in the plasma of LA-apoA-

121 chemokine (C-C motif) ligand 2 (CCL2; MCP-1, monocyte chemotactic protein-1) in the glaucoma eye and

122 this study, we report that immune regulator Monocyte chemotactic protein-1-induced protein 1 (MCPIP1

123 -type zinc finger-containing protein MCPIP1 (monocyte chemotactic protein-1-induced protein-1; also k

124 Levels of monocyte chemotactic protein 1, interleukin-6 (IL-6), an

125 TES, macrophage inflammatory protein 1 beta, monocyte chemotactic protein 1, interleukin-8, and I-309

126 ed higher concentrations of proinflammatory (monocyte chemotactic protein-1, interleukin [IL]-8, IL-6

127 hat when an inducer of hyperalgesic priming (monocyte chemotactic protein 1) is administered at the s

128 e Egr-1-regulated proinflammatory chemokines monocyte chemotactic protein-1, KC growth-regulated prot

129 ocyte chemokine; interleukin-2, -9, and -10; monocyte chemotactic protein-1; leptin; and intracellula

130 types, but the increase in interleukin-6 and monocyte chemotactic protein-1 levels was less prominent

131 Unexpectedly, serum monocyte chemotactic protein-1 levels were 8-fold higher

132 tumor necrosis factor alpha, interleukin 6, monocyte chemotactic protein 1, macrophage inflammatory

133 Interleukin (IL)-1beta, IL-6, monocyte chemotactic protein 1, macrophage inflammatory

134 of B6 mice exhibited a dramatic induction of monocyte chemotactic protein-1, macrophage colony-stimul

135 ificantly higher levels of TNF-alpha, IL-10, monocyte chemotactic protein-1, macrophage inflammatory

136 expressed and secreted (RANTES), IP-10, Mig, monocyte chemotactic protein-1, macrophage inflammatory

137 epithelial neutrophil activating protein-78, monocyte chemotactic protein-1, macrophage inflammatory

138 cyte-reactive chemokines examined, including monocyte chemotactic protein-1, macrophage inflammatory

139 s (lipopolysaccharide-induced CXC chemokine, monocyte chemotactic protein-1, macrophage inflammatory

140 onstrated that other murine beta-chemokines (monocyte chemotactic protein-1, macrophage inflammatory

141 cytokine-induced neutrophil chemoattractant, monocyte chemotactic protein-1, macrophage inflammatory

142 ruitment was associated with upregulation of monocyte chemotactic protein 1 (MCP-1) and inflammatory

143 increased proinflammatory cytokines such as monocyte chemotactic protein 1 (MCP-1) and interleukin 6

144 ice exhibit diminished migratory response to monocyte chemotactic protein 1 (MCP-1) and lipopolysacch

145 after a meal, fructose induced production of monocyte chemotactic protein 1 (MCP-1) and reactive oxyg

146 uM) to phagocytize C. neoformans and produce monocyte chemotactic protein 1 (MCP-1) as a function of

147 e inflammatory protein 1beta (MIP-1beta) and monocyte chemotactic protein 1 (MCP-1) biased the immuni

148 ament fibrocyte (SLF) cell line up-regulates monocyte chemotactic protein 1 (MCP-1) expression after

149 Interleukin-6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) expression were a

150 The early presence of monocyte chemotactic protein 1 (MCP-1) in the CNS provid

151 nt, participates in such cross-talk for CCL2/monocyte chemotactic protein 1 (MCP-1) production in mas

152 lagenase IV (matrix metalloproteinase 9) and monocyte chemotactic protein 1 (MCP-1) promoters up to 1

153 In vitro, several chemokines including monocyte chemotactic protein 1 (MCP-1) protect neurons f

154 anistic analysis revealed that FAS-regulated monocyte chemotactic protein 1 (MCP-1) secretion by BMMS

155 utrophil-activating peptide 78 (ENA-78), and monocyte chemotactic protein 1 (MCP-1) were measured by

156 ll supernatants were assayed for IL-6, IL-8, monocyte chemotactic protein 1 (MCP-1), and FSTL1 by enz

157 nsient depression of interleukin-12 (IL-12), monocyte chemotactic protein 1 (MCP-1), and gamma interf

158 phagocytes, including interleukin-8 (IL-8), monocyte chemotactic protein 1 (MCP-1), and macrophage i

159 duced interleukin-1alpha (IL-1alpha), IL-10, monocyte chemotactic protein 1 (MCP-1), and MCP-3 but no

160 (G-CSF)/keratinocyte-derived chemokine (KC)/monocyte chemotactic protein 1 (MCP-1), and MIP-1alpha f

161 8), interferon-inducible protein 10 (IP-10), monocyte chemotactic protein 1 (MCP-1), and RANTES (regu

162 s of the production of interleukin-8 (IL-8), monocyte chemotactic protein 1 (MCP-1), and soluble inte

163 IP-10), monokine induced by IFN-gamma (MIG), monocyte chemotactic protein 1 (MCP-1), and vascular end

164 efold in the levels of expression of RANTES, monocyte chemotactic protein 1 (MCP-1), gamma-interferon

165 The inflammatory biomarkers monocyte chemotactic protein 1 (MCP-1), IL-6, IL-8, vasc

166 Here we report that the CC chemokine, monocyte chemotactic protein 1 (MCP-1), induced chemotax

167 sion of the chemokines interleukin-8 (IL-8), monocyte chemotactic protein 1 (MCP-1), macrophage infla

168 o normal mice, mice genetically deficient in monocyte chemotactic protein 1 (MCP-1), matrix metallopr

169 increased the expression of the CCR2 ligands monocyte chemotactic protein 1 (MCP-1), MCP-3, and MCP-5

170 Chemotactic peptides, such as Monocyte Chemotactic Protein 1 (MCP-1), play a key role

171 NF-alpha), interleukin 1beta (IL-1beta), and monocyte chemotactic protein 1 (MCP-1).

172 n of the chemokines interleukin-8 (IL-8) and monocyte chemotactic protein 1 (MCP-1).

173 ion, which may be regulated by the chemokine monocyte chemotactic protein 1 (MCP-1).

174 ANTES, IFN-inducible protein 10 (IP-10), and monocyte chemotactic protein 1 (MCP-1).

175 alpha (TNF-alpha), interleukin 6 (IL-6), and monocyte chemotactic protein 1 (MCP-1).

176 gelatinase-associated lipocalin (NGAL), and monocyte chemotactic protein 1 (MCP-1).

177 The CC chemokine, monocyte chemotactic protein, 1 (MCP-1) functions as a m

178 g/mL vs 245.4 pg/mL; P = .012) and decreased monocyte chemotactic protein-1 (MCP-1) (513.3 pg/mL vs 8

179 ratory disease and the levels of chemokines, monocyte chemotactic protein-1 (MCP-1) and CXCL10, in th

180 recruitment to the vessel wall, mediated by monocyte chemotactic protein-1 (MCP-1) and interleukin-8

181 PC) activate endothelial cells to synthesize monocyte chemotactic protein-1 (MCP-1) and interleukin-8

182 ed A549 cells produced mRNAs and protein for monocyte chemotactic protein-1 (MCP-1) and interleukin-8

183 genes involved in atherosclerosis, including monocyte chemotactic protein-1 (MCP-1) and macrophage-co

184 otection assay for intragraft levels of Mig, monocyte chemotactic protein-1 (MCP-1) and regulated on

185 H3, stimulated transcription of the gene for monocyte chemotactic protein-1 (MCP-1) and secretion of

186 inflammatory protein-1alpha (MIP-1alpha) and monocyte chemotactic protein-1 (MCP-1) are abundant in a

187 s had elevated expression of proinflammatory monocyte chemotactic protein-1 (MCP-1) at early time poi

188 Monocyte chemotactic protein-1 (MCP-1) binding to its re

189 d TNFalpha-induced production of eotaxin and monocyte chemotactic protein-1 (MCP-1) but not IL-8.

190 ADMA by high pressure liquid chromatography; monocyte chemotactic protein-1 (MCP-1) by ELISA and NF-K

191 ostate cancer cells produced high amounts of monocyte chemotactic protein-1 (MCP-1) compared with PrE

192 Thrombin-stimulated platelets increased monocyte chemotactic protein-1 (MCP-1) expression by mon

193 The RT-PCR revealed diminished monocyte chemotactic protein-1 (MCP-1) expression in eNO

194 The monocyte chemotactic protein-1 (MCP-1) gene is expressed

195 Monocyte chemotactic protein-1 (MCP-1) has been recogniz

196 acellular adhesion molecule-1 (sICAM-1), and monocyte chemotactic protein-1 (MCP-1) in 2701 participa

197 scular cell adhesion molecule-1 (VCAM-1) and monocyte chemotactic protein-1 (MCP-1) in ischemic muscl

198 Recent studies indicate potential roles of monocyte chemotactic protein-1 (MCP-1) in recruitment of

199 We investigated the potential role of monocyte chemotactic protein-1 (MCP-1) in the pathogenes

200 Monocyte chemotactic protein-1 (MCP-1) induced LFA-1-dep

201 Monocyte chemotactic protein-1 (MCP-1) is a 76-amino-aci

202 R2 receptor activation by its primary ligand monocyte chemotactic protein-1 (MCP-1) is critical for m

203 angiogenesis in lighter skin and report that monocyte chemotactic protein-1 (MCP-1) is secreted by no

204 uantified by HPLC/MS/MS, and adiponectin and monocyte chemotactic protein-1 (MCP-1) levels in culture

205 with talc in vitro, interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) levels were incre

206 S1P and monocyte chemotactic protein-1 (MCP-1) levels were signi

207 Monocyte chemotactic protein-1 (MCP-1) mediates monocyte

208 The monocyte chemotactic protein-1 (MCP-1) receptor (MCP-1R)

209 thelial (HRPE) cell interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) secretion and gen

210 , whereas cells incubated in the presence of monocyte chemotactic protein-1 (MCP-1) showed enhanced I

211 ed in the extent of interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) stimulation betwe

212 ed levels of Toll-like receptor 4 (TLR4) and monocyte chemotactic protein-1 (MCP-1) that colocalize i

213 he cytokine arrays showed that expression of monocyte chemotactic protein-1 (MCP-1) was profoundly re

214 Monocyte chemotactic protein-1 (MCP-1) was suppressed si

215 Lung function, asthma control, and monocyte chemotactic protein-1 (MCP-1) were identified a

216 Inhibition of monocyte chemotactic protein-1 (MCP-1) with the Spiegelm

217 In these studies, we have found that monocyte chemotactic protein-1 (MCP-1), a CC (beta) chem

218 gy of this process, specifically the role of monocyte chemotactic protein-1 (MCP-1), a cytokine known

219 he production (mRNA and secreted protein) of monocyte chemotactic protein-1 (MCP-1), an adipokine pla

220 l T-cell expressed and presumably secreted), monocyte chemotactic protein-1 (MCP-1), and macrophage i

221 e inflammatory protein-1alpha (MIP-1alpha)), monocyte chemotactic protein-1 (MCP-1), and RANTES) and

222 Lower levels of interleukin-6, monocyte chemotactic protein-1 (MCP-1), and soluble CD40

223 bs and complement, induced expression of the monocyte chemotactic protein-1 (MCP-1), IL-8, and RANTES

224 scle actin and of the inflammatory mediators monocyte chemotactic protein-1 (MCP-1), macrophage infla

225 ucible 10-kDa protein (Crg-2/IP-10), RANTES, monocyte chemotactic protein-1 (MCP-1), macrophage infla

226 ctor-alpha (TNFalpha), interleukin 8 (IL-8), monocyte chemotactic protein-1 (MCP-1), plasminogen acti

227 ein levels of C-C chemokine ligand-2 (CCL-2)/monocyte chemotactic protein-1 (MCP-1), tumor necrosis f

228 ety of chemotactic agents, notably including monocyte chemotactic protein-1 (MCP-1).

229 resses receptors to the chemotactic cytokine monocyte chemotactic protein-1 (MCP-1).

230 le-1, vascular cell adhesion molecule-1, and monocyte chemotactic protein-1 (MCP-1).

231 did not significantly decrease the levels of monocyte chemotactic protein-1 (MCP-1); however, neutral

232 ammatory processes mediated by the chemokine monocyte chemotactic protein-1 (MCP-1/CCL2).

233 ses both amyloid precursor protein (APP) and monocyte chemotactic protein-1 (MCP-1; CCL2 in systemati

234 ot macrophage-inflammatory protein-1 alpha), monocyte-chemotactic protein-1 (MCP-1), MCP-3, MCP-4, an

235 rferon-inducible protein 10 [IP-10], RANTES, monocyte chemotactic protein 1 [MCP-1], and macrophage i

236 ttractant, IFNgamma-inducible 10-kd protein, monocyte chemotactic protein 1 [MCP-1], and MCP-2) and t

237 The CC chemokine ligand 2 (CCL2) (JE, monocyte chemotactic protein-1 [MCP-1]) and its CC chemo

238 nterleukin-1beta [IL-1beta]) and chemokines (monocyte chemotactic protein-1 [MCP-1], IL-8, and macrop

239 suppression of LPS-induced cytokine release (monocyte chemotactic protein-1 [MCP-1], macrophage infla

240 fidence interval (CI) 1.8-147; p = 0.01] and monocyte chemotactic protein-1 [(MCP-1) 4.8, CI 1.0-23.0

241 1alpha, but not for [125I]MIP-1beta or [125I]monocyte chemotactic protein-1(MCP-1) binding to intact

242 proteins stromal-derived factor 1 (Sdf1) or monocyte chemotactic protein 1 (Mcp1) enhanced (when sil

243 in turn responded to Reelin by up-regulating monocyte chemotactic protein 1 (MCP1) expression, which

244 Monocyte chemotactic protein 1 (MCP1) induced Pak1 phosp

245 Monocyte chemotactic protein 1 (MCP1) stimulates phospho

246 Monocyte chemotactic protein 1 (MCP1) stimulates vascula

247 e sought to identify the RhoGEFs involved in monocyte chemotactic protein 1 (MCP1)-induced vascular w

248 rleukin-8 (IL-8); formyl-Met-Leu-Phe (fMLP); monocyte chemotactic protein 1 (MCP1).

249 ding tumor necrosis factor-alpha (TNFalpha), monocyte chemotactic protein-1 (MCP1) and interleukin-1-

250 es stimulation of CCR2 chemokine receptor by monocyte chemotactic protein-1 (MCP1).

251 s macrophage inflammatory protein 2 (MIP-2), monocyte chemotactic protein 1, MIP-1beta, inducible pro

252 l response to a monocyte-specific chemokine, monocyte chemotactic protein-1 (mobilization of intracel

253 significantly lower levels of interleukin-6, monocyte chemotactic protein-1, monocyte chemotactic pro

254 In mice deficient for monocyte chemotactic protein-1, monocyte-targeted signal

255 ignificantly decreased intragraft RANTES and monocyte chemotactic protein-1 mRNA expression.

256 procollagen, smooth muscle alpha-actin, and monocyte chemotactic protein-1 mRNA levels while inducin

257 ted expression of interleukin-6, VCAM-1, and monocyte chemotactic protein-1 mRNAs.

258 There were no differences in monocyte chemotactic protein-1 or macrophage inflammator

259 In contrast to IL-8, CGRP did not induce monocyte chemotactic protein-1 or RANTES synthesis, nor

260 ssion of the IL-8 gene but not the genes for monocyte chemotactic protein-1 or RANTES.

261 on IL-12p40, keratinocyte-derived chemokine, monocyte chemotactic protein 1, or macrophage inflammato

262 h plasma levels of interleukin 8 (P = .001), monocyte chemotactic protein 1 (P = .008), and macrophag

263 e colony-stimulating factor (P = 0.002), and monocyte chemotactic protein 1 (P = 0.007).

264 te-macrophage colony-stimulating factor, and monocyte chemotactic protein-1 (p < .05 for all).

265 ule-1 (P < .001), interleukin-10 (P = .041), monocyte chemotactic protein-1 (P = .046), placental gro

266 interleukin-6, tumor necrosis factor-alpha, monocyte chemotactic protein-1, P-selectin, and E-select

267 xplants with antibodies to CCR2 receptor and monocyte chemotactic protein 1 prevented entry of monocy

268 matory cytokines (IL-6, IL-12, TNFalpha, and monocyte chemotactic protein 1) produced by bone marrow-

269 IL-6, vascular endothelial growth factor and monocyte chemotactic protein-1 production and resistance

270 ll as other statins, also reduced RANTES and monocyte chemotactic protein-1 production in mouse endot

271 rosclerotic plaques as well as a decrease in monocyte chemotactic protein-1 production, all of which

272 5(+) monocytes in response to increased lung monocyte chemotactic protein-1 production.

273 a, macrophage inflammatory protein-1beta, JE/monocyte chemotactic protein-1, RANTES (regulated upon a

274 ine, macrophage inflammatory protein-1alpha, monocyte chemotactic protein-1, RANTES, and tumor necros

275 nd osteoclastogenesis-such as interleukin 6, monocyte-chemotactic protein 1, receptor activator of nu

276 icularly for interleukin IL-1beta, IL-6, and monocyte chemotactic protein-1, relative to stimulation

277 d interferon-gamma-inducible protein (IP)-10/monocyte chemotactic protein-1 remained depressed, where

278 cytokines examined, such as IL-6, IL-10, and monocyte chemotactic protein-1, showed no consistent dif

279 n contrast, the chemokines interleukin-8 and monocyte chemotactic protein-1 stayed relatively high fr

280 lammatory protein (MIP)-1alpha , MIP-1beta , monocyte chemotactic protein 1, thymus-and-activation-re

281 genase 1 hypoxia-inducible factor 1 (HIF-1), monocyte chemotactic protein 1, transforming growth fact

282 markers, including myeloperoxidase activity, monocyte chemotactic protein-1, tumor necrosis factor-al

283 interleukin-6, tumor necrosis factor-alpha, monocyte chemotactic protein-1, vascular cell adhesion m

284 f the proinflammatory and profibrotic genes (monocyte chemotactic protein-1, vascular endothelial gro

285 Monocyte chemotactic protein 1 was intensely up-regulate

286 ross endothelial cells expressing VCAM-1 and monocyte chemotactic protein-1 was aberrant compared wit

287 The decrease in lesional monocyte chemotactic protein-1 was associated with the s

288 0 is driven by inducible protein-10, whereas monocyte chemotactic protein-1 was central in non-spinal

289 production of interferon-gamma, RANTES, and monocyte chemotactic protein-1 was elevated in TNF KO mi

290 es through a porous membrane, in response to monocyte chemotactic protein-1, was blocked when the mem

291 cyclooxygenase 2, as well as proinflammatory monocyte chemotactic protein 1 were decreased in respons

292 s of IL-1RA, IL-6, IL-8, IL-15, eotaxin, and monocyte chemotactic protein 1 were higher in deceased p

293 L-6), macrophage inflammatory protein 2, and monocyte chemotactic protein 1 were immune markers of mo

294 rleukin-8, growth-related peptide-alpha, and monocyte chemotactic protein-1 were constitutively relea

295 factor-alpha, interleukin (IL)-6, IL-10, and monocyte chemotactic protein-1 were elevated 24 hours af

296 macrophage inflammatory protein-1 alpha and monocyte chemotactic protein-1 were only elevated in tis

297 tion end-products, plasma interleukin-6, and monocyte chemotactic protein-1 were sampled preextracorp

298 r-alpha, chemokine (C-C motif) ligand 5, and monocyte chemotactic protein-1, when cocultured with tro

299 SA-GROalpha-gamma), CCL5 (RANTES), and CCL2 (monocyte chemotactic protein-1), which have been implica

300 okines RANTES, IFN-inducible protein-10, and monocyte chemotactic protein-1, while LTalphabeta is req